Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Repligen Corporation Common Stock — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.23 (market cap $12.90B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and Repligen Corporation Common Stock for 0 Days on average.
| EMB | RGEN | |
|---|---|---|
Market Cap | $12.90B | $11.14B |
Volume | 8,768,615 | 1,259,263 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $194.57 |
52-Week Low | $90.14 | $102.87 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.26, up 0.2% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The stock faces resistance near $91-92 while support holds at $90. Recent corporate actions include scheduled dividend payments through October 2026, though key valuation metrics remain unavailable for fundamental assessment.
The outlook remains cautious given the bearish technical setup and limited fundamental visibility. Investment opportunity hinges on future financial disclosures, while risks include market volatility from rising bond yields and emerging market exposure. Analyst sentiment suggests EMB's returns will primarily come from yield rather than price appreciation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
